¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-21

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
 2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-21
±³À°ÀÏÀÚ : 2019-11-21
±³À°Àå¼Ò : Àá½Ç ·Ôµ¥È£ÅÚ Å©¸®½ºÅ»·ë  
±³À°ÁÖÁ¦ : 2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 15 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í »çÀüµî·Ï(Àü¹®ÀÇ): 5¸¸¿ø ÇöÀåµî·Ï(Àü¹®ÀÇ): 7¸¸¿ø ÇöÀåµî·Ï(Àü°øÀÇ/Çлý/ÀüÀÓÀÇ/°£È£»ç/±âŸ): 5¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:00~09:25 Tracing genomic rearrangements in the mutational history of lung adenocarcinomas  ÁÖ¿µ¼®(KAIST) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:25~09:50 Mutation signatures in public cancer genomes  ±èŹÎ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 09:50~10:15 Air pollution and epigenetic alteration  ±è¿ìÁø(°­¿øÀÇ´ë) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2 10:15~10:40 Air Pollution and Lung Caner  À±Çü±Ô(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:00~09:25 An introduction to Radiomics (I): Basics  ±èÇüÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:25~09:50 Radiomics in lung cancer from basics to advanced: A pragmatic approach for real-world application  ÀÌÈ£¿¬(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 09:50~10:15 AI in medical imaging: current issues and challenges  ±èÈÖ¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 3 10:15~10:40 AI applications in lung cancer  ÀÌ»ó¹Î(¿ï»êÀÇ´ë) 
È޽Ġ11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 10:40~11:10 È޽Ġ () 
±³À°½Ã°£ 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 11:10~11:50 Molecular characteristics of Malignant Pleural Mesothelioma  Raphael Bueno(Brigham and Women) 
Åä·Ð 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 11:50~12:00 Q & A  Raphael Bueno(Brigham and Women) 
½Ä»ç 11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 12:00~12:40 Luncheon Symposium I  ¾È¸íÁÖ(¼º±Õ°üÀÇ´ë) 
È޽Ġ11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 12:40~13:10 È޽Ġ () 
±³À°½Ã°£ 11-21 Crystal 1 13:10~13:35 Immunotherapy for challenging patients  ÃÖâ¹Î(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 1 13:35~14:00 Re-emerging role of anti-angiogenic inhibitors in immunotherapy era  ±è¹Ì¼Ò(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 1 14:00~14:25 Can chemoimmunotherapy or dual immunotherapy challenge immuno-monotherapy?  ÀÌ°æ¿ø(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 1 14:25~14:50 Immune checkpoint inhibitor for operable NSCLC  ¹Ú»ó°ï(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 2 13:10~13:35 SBRT for centrally located lung cancer  ÀÓäȫ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 2 13:35~14:00 Current status and perspectives of radiation therapy in the era of immunotherapy  À̱ÔÂù(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 2 14:00~14:25 Patient selection for proton therapy in lung cancer  ¼­¾ç±Ç(±¹¸³¾Ï¼¾Å¸) 
±³À°½Ã°£ 11-21 Crystal 2 14:25~14:50 Application of liquid biopsy in lung cancer patients receiving radiotherapy  ³ëÀç¸í(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-21 »çÆÄÀ̾î b·ë 13:10~13:35 Basic concepts and clinical applications of Electromagnetic Navigation Bronchoscopy  Áö¿øÁØ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-21 »çÆÄÀ̾î b·ë 13:35~14:00 Hands-on Session1. Electromagentic Navigation Bronchoscopy  À±È£ÀÏ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-21 »çÆÄÀ̾î b·ë 14:00~14:25 Hands-on Session2. Electromagentic Navigation Bronchoscopy  ÀÌ°æÁ¾(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-21 »çÆÄÀ̾î b·ë 14:25~14:50 Hands-on Session3. Electromagentic Navigation Bronchoscopy  ¹Úµ¿ÀÏ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 1 14:50~15:50 Oral Presentation I.  ³ª±¹ÁÖ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 2 14:50~15:50 Oral Presentation II  ÀÌÀçö(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 3 14:50~15:10 Surgery for Malignant Pleural Mesothelioma  Raphael Bueno(Brigham and Women) 
±³À°½Ã°£ 11-21 Crystal 3 15:10~15:30 Radiotherapy for Malignant Pleural Mesothelioma  ±è¿¬½Ç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 3 15:30~15:50 Systemic Treatment for Malignant Pleural Mesothelioma  ¾ÈÈñ°æ(°¡ÃµÀÇ´ë) 
È޽Ġ11-21 Àá½Ç ·Ôµ¥È£ÅÚ Crystal 1,2,3 15:50~16:10 È޽Ġ () 
±³À°½Ã°£ 11-21 Crystal 1 16:10~16:35 Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC  À̼¼ÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 1 16:35~17:00 Characteristics of anti-PD-1-unresponsive CD8+ T cells in NSCLC  ½ÅÀÇö(KAIST) 
±³À°½Ã°£ 11-21 Crystal 1 17:00~17:25 Tumor microenvironment and immune checkpoint blockade in NSCLC  ÀüÀ±°æ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 1 17:25~17:50 Regulation and function of a novel IL-17-producing T cell population in tumor  Á¤¿¬¼®(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-21 Crystal 2,3 16:10~16:35 Genomic landscape of SCLC  ¹ÌÁ¤() 
±³À°½Ã°£ 11-21 Crystal 2,3 16:35~17:00 Immunotherapy for SCLC  ¹ÌÁ¤() 
±³À°½Ã°£ 11-21 Crystal 2,3 17:00~17:25 Role of surgery in LD-SCLC  Yasuhiro Tsutani(Hiroshima University) 
±³À°½Ã°£ 11-21 Crystal 2,3 17:25~17:50 PCI issue  Takashi Seto(National Kyushu Cancer) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019³â ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ : 2019-11-21""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸ Á¦59Â÷ Ãß°èÇмú´ëȸ : 2019-11-21
´ÙÀ½±Û ÀÎÁ¦´ëÇб³ »ó°è¹éº´¿ø 2019 ³ë¿ø±¸ÀÇ»çȸ ÇϹݱ⠿¬¼ö±³À° : 2019-11-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21030 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (2ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-28 0 5 2024-06-18
21029 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-28 0 8 2024-06-18
21028 ¼­¿ï 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-28 0 11 2024-06-18
21027 ºÎ»ê ´ëÇѽÉÀåÇÐȸ ±âÃÊ°úÇבּ¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö 2024 : 2024-06-28 0 6 2024-06-18
21026 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾƳ»ºÐºñÇÐȸ ºñ¸¸¿¬±¸Áý´ãȸ 2024³â 1Â÷ : 2024-06-27 0 7 2024-06-18
21025 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 3Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 2 2024-06-18
21024 ºÎ»ê Á¦11Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Ãá°èÁ¾ÇÕ½ÉÆ÷Áö¾ö 1ÀÏÂ÷ : 2024-06-27 0 6 2024-06-18
21023 ´ë±¸ ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ ´ë±¸°æºÏÁöȸ 3Â÷ Áý´ãȸ : 2024-06-27 0 4 2024-06-18
21022 ¼­¿ï ´ëÇѼҾƸ¶ÃëÇÐȸ ¿Â¶óÀÎ 2024³â Èñ±Í³­Ä¡ Áúȯ ¸¶Ãë ÇÁ·ÎÅäÄÝ ¿þºñ³ª : 2024-06-27 0 6 2024-06-18
21021 ¼­¿ï (1ÀÏÂ÷)2024³â ´ëÇÑô¼öÇÐȸ 2nd ISCoS Regional Symposium : 2024-06-27 0 6 2024-06-18
21020 °­¿ø 2024 ö¿ø±ºÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß(Ä¡¸Å, ¹é³»Àå°ú ³ë¾È) 0 6 2024-06-18
21019 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (1ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-27 0 5 2024-06-18
21018 ÀüºÏ ±º»ê½ÃÀÇ»çȸ ¿¬¼ö±³À°(±â´É¼º ¼ÒÈ­ºÒ·®Áõ, º¸Çè½É»çÀÇ ÃֽŠÀ̽´) : 2024-06-27 0 4 2024-06-18
21017 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 10 2024-06-18
21016 ºÎ»ê 2024 ±ÝÁ¤±¸ÀÇ»çȸ Çмú´ëȸ(¿¹¹æÁ¢Á¾, ÇʼöÀÇ·áÆÐÅ°Áö) : 2024-06-27 0 9 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷